Download App

Log in to access Online Inquiry
Company Overview More
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company’s products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
CEO: Bradway, Robert A.
Market: NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Moomoo > Quotes > AMGN Amgen > Detailed Quotes

AMGN Amgen

244.770+0.810+0.33%
Close 05/19 20:00 ET
244.77000.00%
Pre Mkt Price 05/20 04:00 ET
High
245.860
Open
242.350
Turnover
588.96M
Low
241.860
Pre Close
243.960
Volume
2.41M
Market Cap
130.76B
P/E(TTM)
24.16
52wk High
256.388
Shares
534.20M
P/E(Static)
23.81
52wk Low
195.376
Float Cap
130.38B
Bid/Ask %
0.00%
Historical High
263.971
Shs Float
532.68M
Volume Ratio
0.83
Historical Low
8.531
Dividend TTM
7.22
Div Yield TTM
10000
P/B
142.72
Dividend LFY
2.95%
Div Yield LFY
4085.47%
Turnover Ratio
0.45%
Amplitude
1.64%
Avg Price
243.959
Lot Size
1
Float Cap
130.38B
Bid/Ask %
0.00%
Historical High
263.971
Shs Float
532.68M
Volume Ratio
0.83
Historical Low
8.531
Dividend TTM
7.22
P/B
142.72
Dividend LFY
2.95%
Turnover Ratio
0.45%
Amplitude
1.64%
Avg Price
243.959
Lot Size
1
Price Forecast

No Data

News

Comment